| Literature DB >> 34911725 |
Ya-Ping Huang1,2, Shi Zhang2, Minying Zhang3, Yi Wang2, Wen-Hong Wang2, Jing Li2, Chunjun Li4, Jing-Na Lin4.
Abstract
OBJECTIVES: To explore the prevalence and risk factors of metabolic-associated fatty liver disease (MAFLD) in Tianjin government employees of different genders.Entities:
Keywords: general endocrinology; hepatobiliary disease; hepatology
Mesh:
Year: 2021 PMID: 34911725 PMCID: PMC8679074 DOI: 10.1136/bmjopen-2021-056260
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Clinical characteristics of the study participants by gender and MAFLD*
| Variables | Female 40.4% (n=6828) | t/χ2 | P value | Male 59.6% (n=10 096) | t/χ2 | P value | ||
| Non- MAFLD | MAFLD | Non-MAFLD | MAFLD | |||||
| Age, years | 44.31±13.21 | 52.46±12.30 | −24.07 | <0.001 | 47.04±12.96 | 46.49±11.54 | 2.24 | 0.025 |
| BMI, kg/m2 | 22.82±2.83 | 27.06±3.56 | −46.71 | <0.001 | 24.60±2.90 | 28.24±3.46 | −57.26 | <0.001 |
| ALT, U/L | 14.56±11.95 | 24.85±21.15 | −20.06 | <0.001 | 21.27±15.96 | 35.84±28.02 | −32.01 | <0.001 |
| Cr, µmol/L | 56.85±8.25 | 56.66±9.38 | 0.79 | <0.43 | 76.55±11.95 | 75.60±11.45 | 4.10 | <0.001 |
| SUA, µmol/L | 260.22±55.38 | 309.53±69.75 | −27.69 | <0.001 | 352.91±75.08 | 393.03±83.77 | −25.32 | <0.001 |
| FPG, mg/dL | 90.84±15.05 | 104.67±31.57 | −18.35 | <0.001 | 97.83±23.22 | 106.41±31.61 | −15.52 | <0.001 |
| TC, mmol/L | 4.89±0.98 | 5.33±1.08 | −15.54 | <0.001 | 4.79±0.90 | 5.03±0.94 | −13.18 | <0.001 |
| TG, mg/dL | 82.40 (62.02~110.75) | 138.22 (103.66~190.49) | −36.72 | <0.001 | 106.32 (77.97~147.076) | 163.91 (117.84~230.36) | −40.96 | <0.001 |
| HDL, mmol/L | 1.55±0.30 | 1.38±0.27 | 22.73 | <0.001 | 1.32±0.27 | 1.23±0.29 | 15.97 | <0.001 |
| LDL, mmol/L | 3.22±0.78 | 3.55±0.85 | −14.89 | <0.001 | 3.14±0.73 | 3.26±0.75 | −8.58 | <0.001 |
| TyG index | 8.25±0.50 | 8.88±0.59 | −41.48 | <0.001 | 8.57±0.55 | 9.08±0.62 | −43.61 | <0.001 |
| Metabolic syndrome, | 259 (5.27) | 701 (36.7) | 1125.09 | <0.001 | 1009 (19.76) | 2745 (55.02) | 1343.59 | <0.001 |
| Hyperglycaemia, n (%) | 217 (4.41) | 428 (22.41) | 520.85 | <0.001 | 606 (11.87) | 1242 (24.89) | 286.47 | <0.001 |
| CHD, n (%) | 64 (1.3) | 57 (2.98) | 22.38 | <0.001 | 116 (2.27) | 129 (2.59) | 1.05 | 0.305 |
| Hypertension, n (%) | 812 (16.51) | 794 (41.57) | 480.28 | <0.001 | 1632 (31.96) | 2459 (49.29) | 314.56 | <0.001 |
*Continuous variables are expressed as mean±SD or median (upper quartile to lower quartile), while classified variables are expressed as percentages.
ALT, alanine aminotransferase; BMI, body mass index; CHD, coronary heart disease; Cr, creatinine; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MAFLD, metabolic-associated fatty liver disease; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides; TyG, triglyceride-glucose.
Figure 1Prevalence of MAFLD in different age groups stratified by gender. MAFLD, metabolic-associated fatty liver disease.
Figure 2Percentage of different BMI groups in women and men/BMI groups, G1: <18.5, G2: 18.5~23.9, G3: 23.9~27.9, G4: 27.9~31.9, G5: 31.9~35.9, G6: ≥35.9. BMI, body mass index.
Figure 3Prevalence of MAFLD in BMI groups stratified by gender/BMI groups, G1: <18.5, G2: 18.5~23.9, G3: 23.9~27.9, G4: 27.9~31.9, G5: 31.9~35.9, G6: ≥35.9. BMI, body mass index; MAFLD, metabolic-associated fatty liver disease.
Figure 4Forest map for binary logistic regression analysis of women and men. (A) OR for the association between body mass index (BMI) and MAFLD of women. (B) OR for the association between BMI and MAFLD of men. (C) OR for the association between age and MAFLD of women. (D) OR for the association between age and MAFLD of men. MAFLD, metabolic-associated fatty liver disease.